Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Yu-Tzu Tai, Ph.D., Kihyun Kim, M.D., Xian-Feng Li, M.S., Mariateresa Fulciniti, Ph.D., Weihua Song, M.D., Sabikun Nahar, B.S., Peter Burger, B.S., Mathew J. Rumizen, Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D, Teru Hideshima, M.D., Ph.D., Robert L Schlossman, M.D., Ph.D., Nikhil C. Munshi, Paul Richardson, M.D., Ph.D., Ann Clark, Ph.D., Janet Ogden, Ph.D., Goutopoulos Andreas, Ph.D., Luca Rastelli, Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3848.

https://doi.org/10.1182/blood.V114.22.3848.3848

Published: 2009

Journal Articles

CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades.

Yu-Tzu Tai, PhD, Giovanni Tonon, M.D., Ph.D., Merav Leiba, M.D., Xian-Feng Li, M.S., Peter Burger, B.S., Weihua Song, M.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Nihkil Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2007) 110 (11): 109.

https://doi.org/10.1182/blood.V110.11.109.109

Published: 2007

Journal Articles

Acquisition of New In Vivo Genomic Change over Time in Multiple Myeloma.

Yu-Tzu Tai, PhD, Leutz Buon, M.S., Benjamin King, B.S., Cheng Li Cheng Li, Ph.D., Peter Burger Peter Burger, B.S., Xian-Feng Li, M.S., Weihua Song, M.D., Robert Schlossman, M.D., Paul Richardson, M.D., Kenneth C. Anderson, M.D., Nikhil Munshi, M.D.

Blood (2007) 110 (11): 2481.

https://doi.org/10.1182/blood.V110.11.2481.2481

Published: 2007

Journal Articles

Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.

Yu-Tzu Tai, PhD, Audie G. Rice, Ph.D., Marav Leiba, M.D., Xian-Feng Li, M.S., Peter Burger, B.S., Weihua Song, M.D., Rao Prabhala, Ph.D., Myles Dillon, B.S., Edie Tolan, Ph.D., Xanling Xie, Ph.D., Teru Hideshima, M.D., Ph.D., Noopur Raje, M.D., Paul Richardson, M.D., Nihkil C. Munshi, M.D., Arnon Nagler, M.D., Herve Avet-Loiseau, M.D., Daniel E.H. Afar, Ph.D., Kenneth C. Anderson, M.D.

Blood (2007) 110 (11): 1509.

https://doi.org/10.1182/blood.V110.11.1509.1509

Published: 2007

Journal Articles

Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment.

Merav Leiba, M.D., Jiangchun Xu, M.D., Ph.D., Weihua Song, M.D., Xian-Feng Li, M.S., Peter Burger, B.S., Jennifer Kordich, M.S., Linda Cassiano, B.A., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Teru Hideshima, M.D., Ph.D., Nikhil C. Munshi, M.D., Paul Richardson, M.D., Kenneth C. Anderson, M.D., Yu-Tzu Tai, PhD

Blood (2007) 110 (11): 1503.

https://doi.org/10.1182/blood.V110.11.1503.1503

Published: 2007

Journal Articles

The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.

Yu-Tzu Tai, PhD, Jiangchun Xu, M.D., Xian-Feng Li, M.S., Iris Breitkreutz, M.D., Klaus Podar, M.D. Ph.D., Teru Hideshima, M.D. Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3452.

https://doi.org/10.1182/blood.V108.11.3452.3452

Published: 2006

Journal Articles

Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.

Yu-Tzu Tai, PhD, Xian-Feng Li, M.S., Iris Breitkreutz, M.D., Weihua Song, M.D., Peter Burger, B.S., Matthew Rumizen, Teru Hideshima, M.D. Ph.D., Klaus Podar, M.D. Ph.D., Irene Ghobrial, M.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3460.

https://doi.org/10.1182/blood.V108.11.3460.3460

Published: 2006

Journal Articles

The MEK1/2 Inhibitor AZD6244 (ARRY-142886) Downregulates Constitutive and Adhesion-Induced c- MAF Oncogene Expression and Its Downstream Targets in Human Multiple Myeloma.

Yu-Tzu Tai, PhD, Giovanni Tonon, Ph.D., Xian-Feng Li, M.S., Matthew Rumizen, Weihua Song, M.D., Aileen Morrison, B.S., Peter Burger, B.S., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3463.

https://doi.org/10.1182/blood.V108.11.3463.3463

Published: 2006

Journal Articles

Killing of Drug-Sensitive and Resistant Myeloma Cells and Disruption of Their Bone Marrow Stromal Interaction by HuLuc63, a Novel Humanized Anti-CS1 Monoclonal Antibody.

Yu-Tzu Tai, PhD, Weihua Song, M.D., Xian-Feng Li, M.S., Peter Burger, B.S., Robert Schlossman, M.D., Audie Rice, Ph.D., Anne van Abbema, Ph.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Daniel Afar, Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 3470.

https://doi.org/10.1182/blood.V108.11.3470.3470

Published: 2006

Journal Articles

A Fully Human Antagonist Anti-CD40 Antibody Triggers Significant Antitumor Activity Against Human Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Xian-Feng Li, M.S., Xia Tong2, M.S., Laurence Catley, M.D., Daniel Santos, M.D., Olivier Tournilhac, M.D., Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Mohammad Luqman2, Ph.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 2414.

https://doi.org/10.1182/blood.V104.11.2414.2414

Published: 2004

Journal Articles

Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Laurence Catley, M.D., Xian-Feng Li, M.S., Makoto Hamasaki, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Teru Hideshima, M.D., Ph.D., Dharminder Chauhan, Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Steven P. Streon, M.D., Ph.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 1498.

https://doi.org/10.1182/blood.V104.11.1498.1498

Published: 2004

NARROW

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades.

Acquisition of New In Vivo Genomic Change over Time in Multiple Myeloma.

Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.

Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment.

The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.

Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.

The MEK1/2 Inhibitor AZD6244 (ARRY-142886) Downregulates Constitutive and Adhesion-Induced c- MAF Oncogene Expression and Its Downstream Targets in Human Multiple Myeloma.

Killing of Drug-Sensitive and Resistant Myeloma Cells and Disruption of Their Bone Marrow Stromal Interaction by HuLuc63, a Novel Humanized Anti-CS1 Monoclonal Antibody.

A Fully Human Antagonist Anti-CD40 Antibody Triggers Significant Antitumor Activity Against Human Multiple Myeloma.

Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only